Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:José_María_Fernández_Sousa-Faro
|
| gptkbp:country |
gptkb:Spain
|
| gptkbp:focus |
oncology
marine-derived drugs |
| gptkbp:founded |
1986
|
| gptkbp:founder |
gptkb:José_María_Fernández_Sousa-Faro
|
| gptkbp:headquarters_location |
Colmenar Viejo, Madrid, Spain
|
| https://www.w3.org/2000/01/rdf-schema#label |
PharmaMar
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:languageOfWork |
gptkb:Spanish
|
| gptkbp:listedOn |
gptkb:Madrid_Stock_Exchange
|
| gptkbp:notable_drug |
gptkb:Aplidin
gptkb:Yondelis gptkb:Zepzelca |
| gptkbp:numberOfEmployees |
~500
|
| gptkbp:parentOrganization |
gptkb:Grupo_Zeltia
|
| gptkbp:product |
gptkb:Aplidin
gptkb:Yondelis gptkb:Zepzelca Zepsyre |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
rare diseases
anticancer drugs |
| gptkbp:stockExchange |
gptkb:BME_Spanish_Exchanges
|
| gptkbp:stockSymbol |
gptkb:PHM
|
| gptkbp:subsidiary |
gptkb:Genomica
gptkb:Sylentis |
| gptkbp:website |
https://www.pharmamar.com/
|
| gptkbp:bfsParent |
gptkb:Ana_Palacio
|
| gptkbp:bfsLayer |
6
|